Nxera Pharma News

Nxera Pharma: Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ in Japan

Oct 1 02:00 ET

Nxera Pharma: Notice of a new partnership with Shionogi Pharmaceutical regarding the insomnia remedy “Kubivic tablets” targeting the Japanese market

Oct 1 02:00 ET

Nxera Pharma: Articles of Incorporation 2024/04/01

Sep 4 04:41 ET

Nxera Pharma: Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

Sep 1 19:30 ET

Nxera Pharma: We have received a USD 35 million milestone from Neurocline due to the positive results of the Phase 2 clinical trial of the candidate NBI-1117568 for schizophrenia

Sep 1 19:30 ET

Nxera Pharma: Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

Aug 28 07:05 ET

Nxera Pharma: Good results in phase 2 clinical trials of schizophrenia drug candidate NBI-1117568, which is a partnership program with Neurocline

Aug 28 07:05 ET

Nxera Pharma: Change Report

Aug 16 02:26 ET

Nxera Pharma: Amended Securities Registration Statement (Reference Method)

Aug 9 03:10 ET

Nxera Pharma: Amended Securities Registration Statement (Reference Method)

Aug 9 03:10 ET

Nxera Pharma: Corrected securities registration form (reference method)

Aug 9 03:09 ET

Nxera Pharma: Corrected securities registration form (reference method)

Aug 9 03:08 ET

Nxera Pharma: Confirmatory letter.

Aug 9 03:02 ET

Nxera Pharma: Interim report - 35th period (01/01/2024 - 12/31/2024)

Aug 9 03:01 ET

Nxera Pharma: Business highlights and consolidated performance for the second quarter (interim period) of December 2024 (January-June).

Aug 9 02:30 ET

Nxera Pharma: Consolidated financial results (IFRS) for the six-month period ending on June 30, 2024.

Aug 9 02:30 ET

Nxera Pharma: December 2024, second quarter (interim period) financial results announcement [IFRS] (consolidated).

Aug 9 02:30 ET

Nxera Pharma: Business highlights and consolidated performance for the second quarter and first half of 2024 for Nxera Pharma.

Aug 9 02:30 ET

Nxera Pharma: Change Report (Stock Certificates Eligible for Special Provisions, etc.)

Aug 5 22:32 ET

Nxera Pharma: Change Report (Stock Certificates Eligible for Special Provisions, etc.)

Jul 18 02:51 ET